线粒体功能异常在血管瘤发生发展中的作用机制研究进展

doi:10.19438/j.cjoms.2026.02.013

摘要/Abstract

摘要： 血管瘤是一种由血管内皮细胞（endothelial cells,ECs）异常增殖而引发的常见血管源性肿瘤,早期快速增生可导致外观畸形及功能障碍。目前,其具体发病机制尚未完全阐明。近年研究表明,线粒体功能异常不仅与ECs异常增殖密切相关,更在血管瘤的发生与发展中扮演着关键角色。本文从血管瘤的危险因素、线粒体相关的发病机制及预防和治疗等方面展开重点阐述,为血管瘤的病理机制研究和临床治疗策略的制定提供新的见解和理论依据。

关键词: 血管瘤, 血管内皮细胞, 线粒体功能异常, 危险因素, 异常增殖

Abstract: Hemangioma is a common vascular tumor caused by the abnormal proliferation of vascular endothelial cells; its rapid early growth can lead to disfigurement and functional impairment. The precise pathogenesis remains incompletely understood. Recent studies show that mitochondrial dysfunction is not only closely associated with abnormal endothelial-cell proliferation, but also plays a pivotal role in the initiation and progression of hemangioma. This article focused on elaborating the risk factors of hemangioma, the pathogenesis related to mitochondria, as well as prevention and treatment, providing new insights and theoretical basis for the research on the pathological mechanism of hemangioma and the formulation of noval clinical treatment strategies.

Key words: Hemangioma, Vascular endothelial cell, Mitochondrial dysfunction, Risk factors, Abnormal proliferation

中图分类号:

R739.8

马若妍, 王浚镔, 甄丽晓, 周云彩, 刘学键. 线粒体功能异常在血管瘤发生发展中的作用机制研究进展[J]. 中国口腔颌面外科杂志, 2026, 24(2): 176-184.

Ma Ruoyan, Wang Junbin, Zhen Lixiao, Zhou Yuncai, Liu Xuejian. Research progress on the mechanism of mitochondrial dysfunction in the pathogenesis and progression of hemangiomas[J]. China J Oral Maxillofac Surg, 2026, 24(2): 176-184.

参考文献

[1] 中华医学会整形外科分会血管瘤脉管畸形学组. 血管瘤与脉管畸形诊疗指南(2024版)[J]. 组织工程与重建外科, 2024, 20(1): 1-50.
Chinese society for the study of vascular anomalies(CSSVA). Diagnosis and treatment guidelines for hemangioma and vascular malformations (2024 edition)[J]. Tissue Engineering & Reconstructive Surgery, 2024, 20(1): 1-50.
[2] 潘新元, 黄晖, 韦奎丞, 等. 早期生长反应因子1调控增殖期婴幼儿血管瘤血管内皮生长因子和基质金属蛋白酶-9的表达[J]. 中国当代医药, 2022, 29(33): 5-9, 197.
Pan XY, Huang H, Wei KC, et al.Early growth response factor 1 regulates the expression of vascular endothelial growth factor and matrix metalloproteinase-9 in proliferative infantile hemangiomas[J]. China Modern Medicine, 2022, 29(33): 5-9, 197.
[3] 冯俞欣, 封孝国, 辜奕如, 等. 婴幼儿血管瘤的发病机制及药物治疗研究进展[J]. 现代医药卫生, 2022, 38(17): 2955-2959.
Feng YX, Feng XG, Gu YR, et al.Research progress on the pathogenesis and drug treatment of infantile hemangioma[J]. Journal of Modern Medicine & Health, 2022, 38(17): 2955-2959.
[4] Warburg O.On the origin of cancer cells[J]. Science, 1956, 123(3191): 309-314.
[5] 郑秋鹏, 郭伶俐, 杜晶, 等. 血管瘤及常见血管畸形致病基因的研究进展[J]. 癌变·畸变·突变, 2012, 24(5): 401-404.
Zheng QP, Guo LL, Du J, et al.Research progress on pathogenic genes of hemangioma and common vascular malformations[J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2012, 24(5): 401-404.
[6] Mizawa M, Matsumura K, Hamazaki K, et al. Infantile hemangioma and the risk factors in a Japanese population: a nationwide longitudinal study-the Japan environment and children's study[J]. J Investig Dermatol, 2021, 141(11): 2745-2748.e2.
[7] Sahin G, Düzcan-Kilimci D, Tanyıldız HG.Epidemiological features and risks of hemangiomas[J]. Turk J Pediatr, 2017, 59(6): 664-669.
[8] Castrén E, Salminen P, Vikkula M, et al.Inheritance patterns of infantile hemangioma[J]. Pediatrics, 2016, 138(5): e20161623.
[9] 文莹, 李海鹏, 罗迪贤, 等. 脑海绵状血管瘤遗传基因研究进展[C]//第十五次中国脑血管病大会2015论文汇编. 南京: 江苏省医学会神经病分会, 2015: 321.
Wen Y, Li HP, Luo DX, et al.Research progress on genetic genes of cerebral cavernous hemangioma[C]//Compilation of Papers at the 15th Chinese Cerebrovascular Disease Conference. Nanjing: Neurology Branch of Jiangsu Medical Association; 2015: 321.
[10] Liu H, Zhen C, Xie J, et al.TFAM is an autophagy receptor that limits inflammation by binding to cytoplasmic mitochondrial DNA[J]. Nat Cell Biol, 2024, 26(6): 878-891.
[11] Lu T, Zhang Z, Bi Z, et al.TFAM deficiency in dendritic cells leads to mitochondrial dysfunction and enhanced antitumor immunity through cGAS-STING pathway[J]. J Immunother Cancer, 2023, 11(3): e005432.
[12] Thirupathi A, DeSouza CT. Multi-regulatory network of ROS: the interconnection of ROS, PGC-1 alpha, and AMPK-SIRT1 during exercise[J]. J Physiol Biochem, 2017, 73(4): 487-494.
[13] Zhang L, Jiang J, Xia X.Suppression of retinal neovascularization by small interfering RNA targeting PGC-1α[J]. Int J Mol Med, 2014, 33(6): 1523-1530.
[14] Thom R, Rowe GC, Jang C, et al.Hypoxic induction of vascular endothelial growth factor(VEGF) and angiogenesis in muscle by truncated peroxisome proliferator-activated receptor γ coactivator (PGC)-1α[J]. J Biol Chem, 2014, 289(13): 8810-8817.
[15] Lin X, Zhou Y, Xue L.Mitochondrial complex I subunit MT-ND1 mutations affect disease progression[J]. Heliyon, 2024, 10(7): e28808.
[16] Walter JW, North PE, Waner M, et al.Somatic mutation of vascular endothelial growth factor receptors in juvenile hemangioma[J]. Genes Chromosomes Cancer, 2002, 33(3): 295-303.
[17] Ding Y, Zhang JZ, Yu SR, et al.Risk factors for infantile hemangioma: a meta-analysis[J]. World J Pediatr, 2020, 16(4): 377-384.
[18] Manente AG, Valenti D, Pinton G, et al.Estrogen receptorβactivation impairs mitochondrial oxidative metabolism and affects malignant mesothelioma cell growth in vitro and in vivo[J]. Oncogenesis, 2013, 2(9): e72.
[19] O'Malley J, Kumar R, Inigo J, et al. Mitochondrial stress response and cancer[J]. Trends Cancer, 2020, 6(8): 688-701.
[20] 李永兴, 崔淑方, 孟卫, 等. 线粒体DNA与cGAS-STING固有免疫信号通路的研究前沿[J]. 四川大学学报(医学版) , 2021, 52(3): 387-395.
Li YX, Cui SF, Meng W, et al.Mitochondrial DNA and cGAS-STING innate immune signaling pathway: latest research progress[J]. Journal of Sichuan University(Medical Sciences), 2021, 52(3): 387-395.
[21] Chandel NS, McClintock DS, Feliciano CE, et al. Reactive oxygen species generated at mitochondrial complex Ⅲ stabilize hypoxia-inducible factor-1alpha during hypoxia: a mechanism of O2 sensing[J]. J Biol Chem, 2000, 275(33): 25130-25138.
[22] Mitra R, Fitzsimons HL, Hale T, et al.Recent advances in understanding the molecular basis of infantile haemangioma development[J]. Br J Dermatol, 2024, 191(5): 661-669.
[23] Apte RS, Chen DS, Ferrara N.VEGF in signaling and disease: beyond discovery and development[J]. Cell, 2019, 176(6): 1248-1264.
[24] Chen ZY, Wang QN, Zhu YH, et al.Progress in the treatment of infantile hemangioma[J]. Ann Transl Med, 2019, 7(22): 692.
[25] Zhu J, Thompson CB.Metabolic regulation of cell growth and proliferation[J]. Nat Rev Mol Cell Biol, 2019, 20(7): 436-450.
[26] Li T, Han J, Jia L, et al.PKM2 coordinates glycolysis with mitochondrial fusion and oxidative phosphorylation[J]. Protein Cell, 2019, 10(8): 583-594.
[27] Yang K, Qiu T, Gong X, et al.Integrated nontargeted and targeted metabolomics analyses amino acids metabolism in infantile hemangioma[J]. Front Oncol, 2023, 13: 1132344.
[28] 吴安, 戴伟民, 李运平, 等. 人成纤维细胞生长因子受体1基因表达抑制通过线粒体途径影响血管瘤内皮细胞凋亡的研究[J]. 中国临床药理学杂志, 2022, 38(19): 2316-2319.
Wu A, Dai WM, Li YP, et al.Study on the effect of inhibition of human fibroblast growth factor receptor 1 gene expression on apoptosis of hemangioma endothelial cells through mitochondrial pathways[J]. China Journal of Clinical Pharmacology, 2022, 38(19): 2316-2319.
[29] Acevedo LM, Cheresh DA.Suppressing NFAT increases VEGF signaling in hemangiomas[J]. Cancer Cell, 2008, 14(6): 429-430.
[30] Chiu HY, Tay EXY, Ong DST, et al.Mitochondrial dysfunction at the center of cancer therapy[J]. Antioxid Redox Signal, 2019, 32(5): 309-330.
[31] Li A, Gao M, Jiang W, et al.Mitochondrial dynamics in adult cardiomyocytes and heart diseases[J]. Front Cell Dev Biol, 2020, 8: 584800.
[32] Wallace DC.Mitochondria and cancer[J]. Nat Rev Cancer, 2012, 12(10): 685-698.
[33] Ghosh P, Vidal C, Dey S, et al.Mitochondria targeting as an effective strategy for cancer therapy[J]. Int J Mol Sci, 2020, 21(9): 3363.
[34] Gordillo GM, Biswas A, Singh K, et al.Mitochondria as target for tumor management of hemangioendothelioma[J]. Antioxid Redox Signal, 2021, 34(2): 137-153.
[35] Wen YA, Xiong X, Scott T, et al.The mitochondrial retrograde signaling regulates Wnt signaling to promote tumorigenesis in colon cancer[J]. Cell Death Differ, 2019, 26(10): 1955-1969.
[36] Hanahan D, Weinberg RA.Hallmarks of cancer: the next generation[J]. Cell, 2011, 144(5): 646-674.
[37] Potente M, Carmeliet P.The link between angiogenesis and endothelial metabolism[J]. Annu Rev Physiol, 2017, 79: 43-66.
[38] Sun T, Yuan W, Wei Y, et al.The regulatory role and mechanism of energy metabolism in vascular diseases[J]. Front Biosci (Landmark Ed), 2024, 29(1): 26.
[39] Bierhansl L, Conradi LC, Treps L, et al.Central role of metabolism in endothelial cell function and vascular disease[J]. Physiol (Bethesda), 2017, 32(2): 126-140.
[40] Chen J, Wu D, Dong Z, et al.The expression and role of glycolysis-associated molecules in infantile hemangioma[J]. Life Sci, 2020, 259: 118215.
[41] Polet F, Feron O.Endothelial cell metabolism and tumour angiogenesis: glucose and glutamine as essential fuels and lactate as the driving force[J]. J Intern Med, 2013, 273(2): 156-165.
[42] Yang E, Wang X, Huang S, et al.Shikonin reverses pyruvate kinase isoform M2-mediated propranolol resistance in infantile hemangioma through reactive oxygen species-induced autophagic dysfunction[J]. Cancer Sci, 2023, 114(3): 806-821.
[43] Rohlenova K, Goveia J, García-Caballero M, et al. Single-cell RNA sequencing maps endothelial metabolic plasticity in pathological angiogenesis[J]. Cell Metab, 2020, 31(4): 862-877.e814.
[44] Blecha J, Novais SM, Rohlenova K, et al.Antioxidant defense in quiescent cells determines selectivity of electron transport chain inhibition-induced cell death[J]. Free Radic Biol Med, 2017, 112: 253-266.
[45] Coutelle O, Hornig-Do HT, Witt A, et al.Embelin inhibits endothelial mitochondrial respiration and impairs neoangiogenesis during tumor growth and wound healing[J]. EMBO Mol Med, 2014, 6(5): 624-639.
[46] Marcu R, Zheng Y, Hawkins BJ.Mitochondria and angiogenesis[J]. Adv Exp Med Biol, 2017, 982: 371-406.
[47] Xu X, Pang Y, Fan X.Mitochondria in oxidative stress, inflammation and aging: from mechanisms to therapeutic advances[J]. Signal Transduct Target Ther, 2025, 10(1): 190-219.
[48] Yang F, Lee G, Fan Y.Navigating tumor angiogenesis: therapeutic perspectives and myeloid cell regulation mechanism[J]. Angiogenesis, 2024, 27(3): 333-349.
[49] 龚恩美, 张恒, 卓金伟, 等. 小儿血管瘤血清基质金属蛋白酶组织抑制因子- 1 和血管内皮生长因子水平变化与瘤体增生及预后的相关性分析[J]. 中国妇幼保健, 2025, 40(7): 1225-1229.
Gong EM, Zhang H, Zhuo JW, et al.Correlation analysis of changes in serum matrix metalloproteinase-1 and vascular endothelial growth factor levels with tumor proliferation and prognosis in children with hemangioma[J]. Maternal and Child Health Care of China, 2025, 40(7): 1225-1229.
[50] 王琰淏, 李燕, 张松雨, 等. VEGF、P53、Ki-67 在血管瘤中的表达及临床意义[J]. 实用癌症杂志, 2023, 38(4): 550-553.
Wang YH, Li Y, Zhang SY, et al.Expression and clinical significance of VEGF,P53 and Ki-67 in hemangioma[J]. The Practical Journal of Cancer, 2023, 38(4): 550-553.
[51] Jin JY, Wei XX, Zhi XL, et al.Drp1-dependent mitochondrial fission in cardiovascular disease[J]. Acta Pharmacol Sin, 2021, 42(5): 655-664.
[52] Chan DC.Mitochondrial dynamics and its involvement in disease[J]. Annu Rev Pathol, 2020, 15: 235-259.
[53] Simula L, Campanella M, Campello S.Targeting Drp1 and mitochondrial fission for therapeutic immune modulation[J]. Pharmacol Res, 2019, 146: 104317.
[54] Kashatus DF.The regulation of tumor cell physiology by mitochondrial dynamics[J]. Biochem Biophys Res Commun, 2018, 500(1): 9-16.
[55] Chen W, Zhao H, Li Y.Mitochondrial dynamics in health and disease: mechanisms and potential targets[J]. Signal Transduct Target Ther, 2023, 8(1): 333.
[56] Herkenne S, Ek O, Zamberlan M, et al. Developmental and tumor angiogenesis requires the mitochondria-shaping protein Opa1[J]. Cell Metab, 2020, 31(5): 987-1003.e8.
[57] Anastasia VP, Victoria AK, Vasily NS, et al.Mitochondria in endothelial dysfunction and the relation to cardiovascular disease[J]. Integr Biochem Res, 2024, 8(5): 100345.
[58] Lugus JJ, Ngoh GA, Bachschmid MM, et al.Mitofusins are required for angiogenic function and modulate different signaling pathways in cultured endothelial cells[J]. J Mol Cell Cardiol, 2011, 51(6): 885-893.
[59] Li Y, Chen H, Yang Q, et al.Increased Drp1 promotes autophagy and ESCC progression by mtDNA stress mediated cGAS-STING pathway[J]. J Exp Clin Cancer Res, 2022, 41(1): 76.
[60] Wang J, Li J, Santana-Santos L, et al.A novel strategy for targeted killing of tumor cells: Induction of multipolar acentrosomal mitotic spindles with a quinazolinone derivative mdivi-1[J]. Mol Oncol, 2015, 9(2): 488-502.
[61] She H, Zhu Y, Deng H, et al.Protective effects of dexmedetomidine on the vascular endothelial barrier function by inhibiting mitochondrial fission via ER/Mitochondria contact[J]. Front Cell Dev Biol, 2021, 9: 636327.
[62] Nagarkoti S, Kim YM, Das A, et al. Endothelial Drp1 couples VEGF-induced redox signaling with glycolysis through cysteine oxidation to drive angiogenesis[J]. bioRxiv[Preprint] , 2024, 16:2024.06.15.599174.
[63] Yang K, Li X, Qiu T, et al.Effects of propranolol on glucose metabolism in hemangioma-derived endothelial cells[J]. Biochem Pharmacol, 2023, 218: 115922.
[64] Gorrini C, Harris IS, Mak TW.Modulation of oxidative stress as an anticancer strategy[J]. Nat Rev Drug Discov, 2013, 12(12): 931-947.
[65] Glorieux C, Liu S, Trachootham D, et al.Targeting ROS in cancer: rationale and strategies[J]. Nat Rev Drug Discov, 2024, 23(8): 583-606.
[66] Guo C, Sun L, Chen X, et al.Oxidative stress, mitochondrial damage and neurodegenerative diseases[J]. Neural Regen Res, 2013, 8(21): 2003-2014.
[67] Magar AG, Morya VK, Kwak MK, et al.A Molecular perspective on HIF-1α and angiogenic stimulator networks and their role in solid tumors: an update[J]. Int J Mol Sci, 2024, 25(6): 3313.
[68] Zhao W, Zhuang P, Chen Y, et al."Double-edged sword" effect of reactive oxygen species(ROS) in tumor development and carcinogenesis[J]. Physiol Res, 2023, 72(3): 301-307.
[69] Moloney JN, Cotter TG.ROS signalling in the biology of cancer[J]. Semin Cell Dev Biol, 2018, 80: 50-64.
[70] Ke C, Chen C, Yang M, et al.Revealing the mechanism of 755-nm long-pulsed alexandrite laser in inhibiting infantile hemangioma endothelial cells through transcriptome sequencing[J]. Lasers Med Sci, 2024, 39(1): 37-48.
[71] Poole LP, Macleod KF.Mitophagy in tumorigenesis and metastasis[J]. Cell Mol Life Sci, 2021, 78(8): 3817-3851.
[72] Luo J, Shen S, Xia J, et al.Mitochondria as the essence of Yang Qi in the human body[J]. Phenomics, 2022, 2(5): 336-348.
[73] Kim M, Mahmood M, Reznik E, et al.Mitochondrial DNA is a major source of driver mutations in cancer[J]. Trends Cancer, 2022, 8(12): 1046-1059.
[74] 刘肖楠, 孙淼淼, 严淑萍, 等. 8例梭形细胞血管瘤的临床病理特征分析[J]. 肿瘤基础与临床,2022, 35(6): 495-498.
Liu XN, Sun MM, Yan SP, et al.Clinicopathological characteristics of 8 cases of spindle cell hemangioma[J]. Journal of Basic and Clinical Oncology, 2022, 35(6): 495-498.
[75] Ayturk UM, Couto JA, Hann S, et al.Somatic activating mutations in GNAQ and GNA11 are associated with congenital hemangioma[J]. Am J Hum Genet, 2016, 98(4): 789-795.
[76] Panagopoulos I, Gorunova L, Lobmaier I, et al.Fusion of the COL4A5 gene with NR2F2-AS1 in a hemangioma carrying a t (X;15)(q22;q26) chromosomal translocation[J]. Cancer Genomics Proteomics, 2020, 17(4): 383-390.
[77] Onishi M, Yamano K, Sato M, et al.Molecular mechanisms and physiological functions of mitophagy[J]. EMBO J, 2021, 40(3): e104705.
[78] Lu Y, Li Z, Zhang S, et al.Cellular mitophagy: mechanism, roles in diseases and small molecule pharmacological regulation[J]. Theranostics, 2023, 13(2): 736-766.
[79] Chang JY, Yi HS, Kim HW, et al.Dysregulation of mitophagy in carcinogenesis and tumor progression[J]. Biochim Biophys Acta Bioenerg, 2017, 1858(8): 633-640.
[80] Morciano G, Patergnani S, Bonora M, et al.Mitophagy in cardiovascular diseases[J]. J Clin Med, 2020, 9(3): 892.
[81] Faes S, Santoro T, Demartines N, et al.Evolving significance and future relevance of anti-angiogenic activity of mTOR Inhibitors in cancer therapy[J]. Cancers(Basel), 2017, 9(11): 152.
[82] Zhang L, Wu HW, Yuan W, et al.Estrogen-mediated hemangioma-derived stem cells through estrogen receptor-α for infantile hemangioma[J]. Cancer Manag Res, 2017, 9: 279-286.
[83] Chen S, Wang Y, Zhang H, et al.The antioxidant MitoQ protects against CSE-induced endothelial barrier injury and inflammation by inhibiting ROS and autophagy in human umbilical vein endothelial cells[J]. Int J Biol Sci, 2019, 15(7): 1440-1451.
[84] 颜雪芸, 徐佩尔, 周乐, 等. 普萘洛尔对大鼠心脏细胞线粒体的影响[J]. 中国临床药理学杂志, 2022, 38(15): 1757-1760.
Yan XY, Xu PE, Zhou L, et al.Effect of propranolol on mitochondria in rat heart cells[J]. China Journal of Clinical Pharmacology, 2022, 38(15): 1757-1760.
[85] Tu JB, Dong Q, Hu XY, et al.Proteomic analysis of mitochondria from infantile hemangioma endothelial cells treated with sodium morrhuate and its liposomal formulation[J]. J Biochem Mol Toxicol, 2012, 26(9): 374-380.